Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients

European Journal of Clinical Pharmacology

Volumn 62, Issue 8, 2006, Pages 605-612

  Tarantino, Giovanni ^a   Conca, Paolo ^a   Capone, Domenico ^a   Gentile, Antonio ^a   Polichetti, Giuliano ^a   Basile, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Caffeine intake; Cirrhosis; Liver function; Total overnight salivary caffeine assessment

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; TRANSFORMING GROWTH FACTOR BETA1;

ABSTINENCE; ADULT; ARTICLE; BEVERAGE; COFFEE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FOOD INTAKE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; RELIABILITY; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOTAL OVERNIGHT SALIVARY CAFFEINE ASSESSMENT; VALIDITY;

ADULT; CAFFEINE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; PHENOTYPE; REFERENCE VALUES; SALIVA; SENSITIVITY AND SPECIFICITY;

EID: 33746461421     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0146-7     Document Type: Article

References (37)

1. Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125-134
2. Nordmark A, Lundgren S, Cnattingius S, Rane A (1999) Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol 47:397-402
3. Holstege A, Staiger M, Haag K, Gerok W (1989) Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klin Wochensch 67:6-15
4. Jost G, Wahlländer A, Von Mandach U, Preisig R (1987) Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 7:338-344
5. Lewis FW, Rector WG (1992) Caffeine clearance in cirrhosis: the value of simplified determinations of liver metabolic capacity. J Hepatol 14:157-162
6. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J et al (2000) Evaluation of caffeine as an in vivo probe for CYP1A2 using measurement in plasma, saliva, and urine. Ther Drug Monit 22:409-417
7. Wittayalertpanya S, Israsena S, Thamaree S, Tongnopnoua P, Komolmit P (1996) Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease. Tokai J Exp Clin Med 21:195-201
8. Jover R, Carnicer F, Sanchez-Paya J, Climent E, Sirvent M, Marco JL (1997) Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroen 92:1905-1908
9. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, Dwoskin LP, Crooks PA (2003) A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 27:165-171
10. Carbo M, Segura J, De la Torre R, Badenas JM, Cami J (1989) Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 45:234-240
11. Abernethy DR, Todd EL (1985) Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 28:425-428
12. Broughton LJ, Rogers HJ (1981) Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol 12:155-159
13. Ou-Yang DS, Huang SL, Wang W, Xie HG, Xu ZH, Shu Y, Zhou HH (2000) Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49:145-151
14. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute, 2001 (NIH publ. no. 01-3670)
15. Hayden MR, Tyagi SC (2004) Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 1:10
16. Jehn M, Clark JM, Guallar E (2004) Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27:2422-2428
17. Qureshi M, Khsandwala H, Haq IU, Prasad K (2003) Elevated levels of plasma homocysteine in hypertensive patients with diabetes mellitus. J Cardiovasc Pharmacol Ther 8:261-266
18. Fiellin DA, Carrington Reid M, O'Connor PG (2000) Screening for alcohol problems in primary care. A systematic review. Arch Intern Med 160:1977-1989
19. Bunker ML, McWilliams M (1979) Caffeine content of common beverages. J Am Diet Assoc 74:28-32
20. McCusker RR, Goldberger BA, Cone EJ (2003) Caffeine content of specialty coffees. J Anal Toxicol 27:520-537
21. Miceli JN, Aravind MK, Ferrell WJ (1984) Analysis of caffeine: comparison of the manual enzyme multiplied immunoassay (EMIT), automated EMIT, and high-performance liquid chromatography procedures. Ther Drug Monit 6:344-347
22. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126:529-540
23. Rodopoulos N, Wisen O, Norman A (1995) Caffeine metabolism in patients with chronic liver disease. Scand J Clin Lab Invest 55:229-242
24. Garello E, Battista S, Bar F, Niro GA, Cappello N, Rizzetto M, Molino G (1999) Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations. Dig Dis Sci 44:782-788
25. Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC (2003) Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 38:1227-1236
26. Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M (2000) Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 33:893-901
27. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, Nebert DW (2003) Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 111:45-51
28. Sreekumar R, Rosado B, Rasmussen D, Charlton M (2003) Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38:244-251
29. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, Yudkin JS (1999) Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol 50:221-228
30. Jurgens G, Lange KH, Reuther LO, Rasmussen BB, Brosen K, Christensen HR (2002) Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 71:162-168, Mar
31. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275:2247-2250
32. Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ (2000) Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared to AHR knockout mice. Hepatol Res 17:112-125
33. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828-833
34. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, Omata M (2004) Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 72:52-59
35. Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP (1994) Guillouzo Transforming growth factor-beta 1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol 46:1100-1110
36. Sepulveda-Flores RN, Vera-Cabrera L, Flores-Gutierrez JP, Maldonado-Garza H, Salinas-Garza R, Zorrilla-Blanco P, Bosques-Padilla FJ (2002) Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity. Ann Hepatol 1:36-39
37. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A (2001) Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15:1667-1667